- Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
- Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
- Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
- Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones
- Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors
- Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results
- Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference
- Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease
More ▼
Key statistics
On Thursday, Beam Therapeutics Inc (BEAM:NSQ) closed at 33.04, 94.93% above the 52 week low of 16.95 set on Oct 23, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 34.08 |
---|---|
High | 34.17 |
Low | 32.92 |
Bid | 32.80 |
Offer | 33.90 |
Previous close | 33.96 |
Average volume | 1.09m |
---|---|
Shares outstanding | 81.66m |
Free float | 80.13m |
P/E (TTM) | -- |
Market cap | 2.70bn USD |
EPS (TTM) | -1.87 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 20:15 BST.
More ▼